Business Context and Reporting Period
Amphastar Pharmaceuticals, Inc. (AMPH) filed a Form 8-K on September 15, 2025, reporting the entry into a Material Definitive Agreement. The Company is a Delaware corporation headquartered in Rancho Cucamonga, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the specific transaction costs:
- Total Agreement Cost: Not to exceed approximately $2.8 million (payable in Chinese yuan, adjusted for exchange rates).
- Initial Payment: Approximately $0.3 million paid on the Effective Date (September 15, 2025).
- Additional Costs: Charged on a cost-plus basis for any work outside the original Scope of Work, subject to prior approval.
Material Changes and Transaction Details
The Company entered into a three-year contract research agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin"). Key terms include:
- Scope: Hanxin will develop Recombinant Peptide Research Cell Banks (RCBs) for the Company's product candidate, AMP-107.
- Intellectual Property: The Company will receive a fully paid, exclusive, perpetual, transferable, and sub-licensable worldwide license to the RCBs. All title to the RCBs and related proprietary information belongs to the Company.
- Related Party Transaction: The agreement is a related party transaction. Dr. Jack Zhang (CEO, President, Director) and Dr. Mary Luo (Chairman, COO, Director), along with certain family members, beneficially own a majority of the equity interest in Hanxin.
- Approval: The Audit Committee's independent and disinterested members evaluated and approved the agreement.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or general outlook. Specific risks and contingencies noted include:
- Currency Risk: Payments are made in Chinese yuan, meaning the final cost in USD will fluctuate based on exchange rates.
- Scope Creep: Additional work requested by the Company will incur extra costs on a cost-plus basis.
- Related Party Conflicts: The transaction involves significant ownership by Company executives, requiring specific governance oversight.
Investor Verification Checklist
- Verify the full text of the Agreement and Scope of Work (Appendix A) when filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2025.
- Confirm the exact beneficial ownership percentages of Dr. Jack Zhang and Dr. Mary Luo in Hanxin as disclosed in the 2025 Definitive Proxy Statement (Schedule 14A).
- Monitor future 10-Q filings for the actual USD amount paid versus the $2.8 million cap, considering currency exchange fluctuations.
- Review the development timeline for the AMP-107 product candidate to assess the strategic impact of the RCBs.